On 31 December 2019, WHO was informed of the detection of a cluster of pneumonia of unknown aetiology in Wuhan City, Hubei Province of China. A novel coronavirus (tentatively named 2019-nCoV) was identified as the causative virus on 7 January 2020. Due to its rapid proliferation in China, this new deadly pathogen posed a significant global threat and an Emergency Committee was convened by WHO’s Director General under the International Health Regulations (IHR 2005). COVID-19 was declared a Public Health Emergency of International Concern (PHEIC) on 30 January 2020.
On 29 January 2020, WHO’s Eastern Mediterranean Region reported the detection of its first 2019-nCoV cases. On 11 February 2020, WHO announced “COVID-19” as the official name of the new disease. On 11 March, WHO described the COVID-19 outbreak as a pandemic due to concerns over the geographical spread of the disease, as it already affected countries on all continents.
In 2021, countries in the Region experienced an increase in reported cases and deaths related to COVID-19. The total of 12 219 208 confirmed cases represented more than double the number reported in 2020, which stood at 4 941 451. A higher number of deaths was also reported compared to the previous year (194 245 in 2021 compared to 121 488 in 2020). However, the CFR reported was lower in 2021 (1.8%) compared to 2020 (2.5%). Two waves of the pandemic were observed in 2021 across the Region (Fig. 28). The first wave started in epi-week 5 with a gradual increase until its peak in epi-week 15 with 387 375 reported cases. A steady decline followed with the implementation of strict public health and social measures by governments. The second wave started around week 24, peaking in week 32 with 501 055 cases: the highest recorded number of cases.
Since the beginning of the outbreak, the country that has reported the highest number of total cases in the Region is the Islamic Republic of Iran (6 195 403 cases; 36% of the Region’s total), followed by Iraq (2 093 891; 12.2%) and Pakistan (1 296 527; 7.5%). The Islamic Republic of Iran also reported the highest number of COVID-19 deaths (131 639; CFR 2.1%) in the Region, followed by Pakistan (28 941; CFR 2.2%) and Tunisia (25 586; CFR 3.5%). The highest CFRs were reported by Yemen (19.6%) and Sudan (7.1%), while the lowest were reported by Qatar (0.25%), the United Arab Emirates (0.28%) and Bahrain (0.49%).
In terms of testing, 294 992 406 laboratory PCR tests have been conducted since the start of the outbreak across the Region. This includes 5 537 220 tests in week 52 of 2021, showing a 9.6% increase compared to the previous week (5 053 882 tests conducted in week 51). The United Arab Emirates reported the highest cumulative number of PCR tests conducted (111.2 million), followed by the Islamic Republic of Iran (42.1 million) and Saudi Arabia (33.3 million). The average positivity rate for the Region is 5.8%.
In terms of laboratory capacities, 15 countries reported having domestic genome sequencing capabilities to detect SARS-CoV-2 variants of concern. The other seven countries received WHO support to sequence abroad and are receiving support to strengthen local sequencing capacity using MiniOn technology.
Meanwhile, COVID-19 vaccination continues across the Region. The total number of doses administered as of 31 December 2021 in the Region’s 22 countries is 537 963 306. Pakistan has administered the highest number of doses (156 623 021), followed by the Islamic Republic of Iran (119 325 720) and Egypt (56 694 353). On the contrary, the total number of administrated doses in Djibouti has only reached 133 933, and in 659 712 in Yemen. Seven countries succeeded to vaccinate more than 40% of their target population, while five countries are still falling behind with less than 10% of target population fully vaccinated.
Since the start of the pandemic, a total of five variants of concern were reported across the Region. Among these variants, four were reported in 2021 (see Table 3). The Delta variant was mainly associated with increased disease severity while the Omicron variant showed high transmissibility. In total, 14 countries of the Region had reported the detection of the Omicron variant in 2021.
Fig. 28. Distribution of daily COVID-19 cases, deaths and CFR in the Region, epidemiological week 1-52, 2021
WHO has continued to provide support to countries through the development and dissemination of various technical guidance documents to strengthen capacities for surveillance, laboratory, clinical management, IPC and risk communication and community engagement, to improve detection and response capacities. WHO also helped procure personal protective equipment (PPE) and testing kits, conduct online training, and accelerate research and development through the solidarity trials and unity studies to help test and develop therapeutics, diagnostics and vaccines.
Nearly 2 years have passed since the first report of a COVID-19 case detected in the Region. At the time, the WHO Regional Office for the Eastern Mediterranean had activated the Incident Management Support Team (IMST) structure to support and coordinate readiness and response efforts. The IMST provided linked the headquarter-level IMST and WHO country offices for a methodical response both at the regional level and through technical support to countries in the Region. Since its establishment, the IMST has coordinated the COVID-19 response by providing strategic, operational and technical support to countries. In December 2020, the IMST structure was revised to by adding the COVID-19 vaccine pillar, to adapt to the evolving COVID-19 situation and response.
Coordination, leadership, strategic and technical guidance, surveillance, capacity-building, logistics, research, and innovation to adapt to the everchanging situation, are the main roles of the IMST. With over US$ 483 million mobilized for the regional COVID-19 response in 2020, the Regional Office had secured the highest amount of funds and had the highest utilization rate of funds received among WHO regional offices. The Dubai logistics hub had dispatched a record-breaking value of supplies in 2020 (US$ 58.9 million) in 2020, serving as the largest repository of medical equipment and supplies in the world.
Communicating effectively with WHO country offices, partners, communities and other stakeholders was an essential part of the response, including providing accurate and timely information to the general public especially regarding mask wearing, fighting the the “infodemic”, and combatting vaccine hesitancy. External communication and risk communication and community engagement were paired with regular technical guidance tailored to the regional situation. Guidance to countries included interim guidance documents, COVID-19 response review missions, training courses and webinars. In addition, the IMST developed technical tools to improve data management and analysis, including through interactive dashboards and modelling tools, to assist countries in implementing the most effective measures nationally and sub-nationally.
To strengthen its technical support to countries, the IMST deployed experts to conduct initial assessment missions in eight countries in early 2020, followed by and review missions of the COVID-19 response in four countries in late 2020: Afghanistan, Pakistan, Tunisia, and Lebanon. In 2021, three COVID-19 response review missions were conducted to Jordan, Somalia, and Saudi Arabia. The purpose of these missions was to identify and document strengths and areas for improvement while supporting ministries of health to review and assess their national COVID-19 response. In the missions, experts reviewed background documents, engaged with key stakeholders and conducted site visits. Technical and operational advice was given to stakeholders throughout, and recommendations were then made in the context of the emergency response and for longer term health system strengthening.
Fig. 29. Geographical distribution of COVID-19 cases and deaths per million reported from the Region, January to December 2021
Influenza activity in the Region during the COVID-19 pandemic
Influenza continues to pose a persistent threat in its epidemic and pandemic forms. In 2021, a decline in influenza activity has been seen in the Region, a trend witnessed in other parts of the world as well. However, compared to 2020, the year (2021) also saw a revival of attention towards influenza surveillance.
Before the COVID-19 pandemic, around 19 countries in the Region had functional sentinel influenza surveillance systems that were regularly reporting epidemiological and virologic data to WHO global and regional platforms. However, in 2021 only 11 countries were reporting their data for many reasons, mainly difficulties in maintaining influenza surveillance due to overwhelmed staff and/or diversion of influenza staff to respond to the COVID-19 pandemic.
In the 2020–2021 season, despite the fact that the number of enrolled patients at sentinel sites has maintained high levels as shown in Fig. 30; however, there has been a remarkable decline in the number of specimens tested for influenza (44 764 specimens out of 166 576 enrolled patients) when compared to previous seasons. This can be explained by a high volume of patients with respiratory symptoms presented at health care facilities during the COVID-19 pandemic; nonetheless, these patients were not being tested for influenza, instead health professionals have been focusing on COVID-19 diagnostics, overlooking influenza. On another note, countries in other WHO regions that maintained the systematic testing of influenza during the pandemic, still witnessed a decrease or absence of influenza activity. Hence, it is not surprising to see how a non-influenza pandemic virus, with similar mode of transmission to that of influenza viruses, can partially mitigate the spread of seasonal influenza. This decline in influenza virus activity has been observed in the Region, as well as in several WHO regions.
Fig. 30. Number of enrolled patients, tested specimens, and percent positive influenza specimens by analytical period, countries in the Region, from 2016 to 2017 until 2020 to 2021
Interventions against SARS-CoV2 transmission may explain to some extent the low influenza activity witnessed globally. The IPCs and NPIs measures that are being adopted to prevent the spread of COVID-19 in communities are similar to those recommended for other respiratory diseases, such as influenza, hence the decrease in influenza activity during the pandemic period.
One important point to highlight, though, is the solid infrastructure of the sentinel influenza surveillance system that played a major role in many countries of the Region in the early response to the pandemic. This infrastructure can be represented by the sentinel network being readily available for use for COVID-19 isolation and collection of specimens, trained and experienced influenza personnel (on IPC measures, specimen collection and handling, recording and reporting data), capacitated laboratories and national influenza centres in testing influenza and other viral pathogens, available influenza guidelines/SOPs, and the use of influenza pandemic preparedness plans by countries and their adoption (after a few amendments) and implementation at the beginning and throughout of the pandemic.
Table 3. Infectious disease outbreaks reported from countries of the Region in 2021
Disease
|
Country
|
First reported case
|
Last reported case
|
Total cases*
|
Deaths
|
CFR (%)
|
Acute watery diarrhoea
|
Afghanistan
|
September 2021
|
December 2021
|
4915
|
8
|
0.16
|
Cholera
|
Somalia
|
January 2021
|
December 2021
|
4577
|
36
|
0.8
|
Yemen
|
January 2021
|
April 2021
|
25 956
|
16
|
0.06
|
Crimean-Congo haemorrhagic fever
|
Afghanistan
|
January 2021
|
December 2021
|
87
|
5
|
5.7
|
Pakistan
|
January 2021
|
December 2021
|
28
|
-
|
|
Iraq
|
May 2021
|
December 2021
|
45
|
13
|
29
|
|
|
|
|
|
|
|
Dengue fever
|
Afghanistan
|
September 2021
|
December 2021
|
761
|
1
|
0.13
|
Pakistan
|
January 2021
|
November 2021
|
41 500
|
228
|
0.09
|
Sudan
|
October 2021
|
December 2021
|
738
|
4
|
0.54
|
Yemen
|
January 2021
|
November 2021
|
1061
|
66
|
6.2
|
Diphtheria
|
Sudan
|
February 2021
|
December 2021
|
11
|
14
|
78
|
Yemen
|
January 2021
|
December 2021
|
7874
|
500
|
6.3
|
Extensively drug-resistant typhoid fever
|
Pakistan
|
January 2021
|
August 2021
|
1792
|
-
|
-
|
Hepatitis E
|
Sudan
|
May 2021
|
December 2021
|
1944
|
24
|
1.2
|
Measles
|
Afghanistan
|
January 2021
|
December 2021
|
30199
|
108
|
3.6
|
Somalia
|
January 2021
|
December 2021
|
7494
|
-
|
-
|
Northwest Syria
|
January 2021
|
December 2021
|
334
|
-
|
-
|
Middle East respiratory syndrome
|
Saudi Arabia
|
January 2021
|
December 2021
|
10
|
3
|
30
|
Saudi Arabia
|
January 2021
|
December 2021
|
2
|
1
|
50
|
Saudi Arabia
|
January 2021
|
December 2021
|
1
|
1
|
100
|
Saudi Arabia
|
January 2021
|
December 2021
|
2
|
1
|
100
|
Saudi Arabia
|
January 2021
|
December 2021
|
1
|
0
|
|
United Arab Emirates
|
January 2021
|
December 2021
|
01
|
-
|
-
|
United Arab Emirates
|
January 2021
|
December 2021
|
01
|
|
|
Poliomyelitis (WPV1/cVDPV)
|
Afghanistan
|
January 2021
|
December 2021
|
4
|
-
|
-
|
Pakistan
|
January 2021
|
December 2021
|
1
|
-
|
-
|
Poliomyelitis (cVDPV)
|
Djibouti
|
January 2021
|
December 2021
|
|
|
|
Egypt
|
January 2021
|
December 2021
|
|
|
|
Somalia
|
January 2021
|
December 2021
|
|
|
|
Sudan
|
January 2021
|
December 2021
|
|
|
|
Yemen
|
January 2021
|
December 2021
|
|
|
|
COVID-19
|
Afghanistan
|
January 2021
|
December 2021
|
52 586
|
2211
|
4.2
|
Bahrain
|
January 2021
|
December 2021
|
105526
|
5145
|
4.9
|
Djibouti
|
January 2021
|
December 2021
|
189387
|
1042
|
0.6
|
Egypt
|
January 2021
|
December 2021
|
7825
|
128
|
1.6
|
Islamic Republic of Iran
|
January 2021
|
December 2021
|
247513
|
14121
|
5.7
|
Iraq
|
January 2021
|
December 2021
|
4969258
|
76383
|
1.5
|
Jordan
|
January 2021
|
December 2021
|
1498449
|
11345
|
0.8
|
Kuwait
|
January 2021
|
December 2021
|
768911
|
8819
|
1.1
|
Lebanon
|
January 2021
|
December 2021
|
266551
|
1534
|
0.6
|
Libya
|
January 2021
|
December 2021
|
546427
|
7374
|
1.3
|
Morocco
|
January 2021
|
December 2021
|
287990
|
4223
|
1.5
|
Occupied Palestinian territory
|
January 2021
|
December 2021
|
523899
|
7461
|
1.4
|
Oman
|
January 2021
|
December 2021
|
315157
|
3405
|
1.1
|
Pakistan
|
January 2021
|
December 2021
|
176741
|
2617
|
1.5
|
Qatar
|
January 2021
|
December 2021
|
813755
|
18757
|
2.3
|
Saudi Arabia
|
January 2021
|
December 2021
|
106694
|
373
|
0.3
|
Somalia
|
January 2021
|
December 2021
|
193495
|
2654
|
1.4
|
Sudan
|
January 2021
|
December 2021
|
18818
|
1203
|
6.4
|
Syrian Arab Republic
|
January 2021
|
December 2021
|
21258
|
1761
|
8.3
|
Tunisia
|
January 2021
|
December 2021
|
38844
|
2186
|
5.6
|
United Arab Emirates
|
January 2021
|
December 2021
|
587286
|
20846
|
3.5
|
Yemen
|
January 2021
|
December 2021
|
554115
|
1495
|
0.3
|
*Includes both suspected and laboratory-confirmed cases